Astellas Pharma ((ALPMF)), Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Astellas Pharma is conducting a Phase 1 clinical study titled ‘A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation.’ The study aims to assess the safety and tolerability of ASP3082 in adults with advanced solid tumors featuring the KRAS G12D mutation, a significant target in cancer treatment.
The study tests ASP3082, an experimental drug administered via intravenous infusion, both as a standalone treatment and in combination with other drugs like Cetuximab, FOLFIRINOX, and Pembrolizumab. The goal is to determine the appropriate dosage and evaluate its effectiveness in treating the targeted mutation.
This open-label, non-randomized study follows a sequential intervention model, focusing primarily on treatment. Participants are grouped to receive varying doses of ASP3082, with or without additional drugs, to identify the optimal treatment regimen.
The study began on June 8, 2022, and is currently recruiting participants. The primary completion and estimated completion dates are set for June 30, 2025, marking key milestones in the study’s progress.
For investors, the successful development of ASP3082 could enhance Astellas Pharma’s market position, potentially boosting stock performance. The study’s focus on a specific mutation offers a competitive edge in the oncology sector, where targeted therapies are increasingly valuable.
The study is ongoing, with further details available on the ClinicalTrials portal.